8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 23, 2013

Shire plc

_________________________________________________________________________

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands

_________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630                                                  98-0601486

(Commission File Number)                (IRS Employer Identification No.)

5 Riverwalk, Citywest Business Campus, Dublin

24, Republic of Ireland

_________________________________________________________________________

(Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               +353 1 429 7700

_________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02.   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The Board of Directors of Shire plc (“Shire”) announced on October 23, 2013 that Dominic Blakemore will join the Board of Directors as a non executive director with effect from January 1, 2014.  On joining the Board, Mr. Blakemore will become a member of Shire's Audit, Compliance & Risk Committee.  Shire has issued a press release attached as Exhibit 99.01 which is incorporated by reference herein.

Item 9.01.   Financial Statements and Exhibits

(d)  Exhibits.  The following exhibit is filed herewith:

99.01         Press Release dated October 23, 2013

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC
By:	/s/ T May
	Name:   Tatjana May
	Title:   General Counsel

Dated: October 23, 2013

EXHIBIT INDEX
Number	Description
99.01	Press release dated October 23, 2013

EX-99.1

Exhibit 99.01

Press Release
www.shire.com

Non Executive Director Appointment

Dublin, Ireland – 23 October 2013 – Shire plc (LSE: SHP, NASDAQ: SHPG), announces that Dominic Blakemore will join its Board of Directors effective 1 January 2014 as non executive director and member of the Audit, Compliance & Risk Committee.

Dominic is Group Finance Director of Compass Group PLC.  Prior to this he was Chief Financial Officer at Iglo Foods Group and Finance & Strategy Director of Cadbury plc. He spent his earlier career years at PwC (PricewaterhouseCoopers), where his work included advising pharmaceutical sector clients.

Matthew Emmens, Chairman of Shire commented:

“The Shire Board will benefit from Dominic’s strategic and financial experience. We look forward to him joining the Board.”

Dominic Blakemore added:

“Shire has an excellent track record of growth and a clear strategy. I look forward to playing a part in this growing company’s future.”

There is no further information that is required to be disclosed under 9.6.13R of the UK Listing Rules.

For further information please contact:

Investor Relations
Eric Rojas	erojas@shire.com	+1 781 482 0999
Sarah Elton-Farr	seltonfarr@shire.com	+44 1256 894157
Media
Jessica Mann	jmann@shire.com	+44 1256 894 280

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

www.shire.com

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX